2024 targets achieved; markets appreciated shareholder rewards
30/01/25 -"Even though Q4 results were somewhat behind the consensus, Sanofi slightly exceeded its 2024 guidance. The 2025 outlook was encouraging. Moreover, the investors welcomed the management’s ..."
Pages
72
Language
English
Published on
30/01/25
You may also be interested by these reports :
07/02/25
The Q4 operating profitability was somewhat ahead of the street’s expectations, though sales lagged the consensus by c.2%. Moreover, the 2025 outlook ...
06/02/25
The Q4 results exceeded the street’s expectations, while the 2025 outlook was in line with consensus estimates. Moreover, the firm raised its ...
06/02/25
The Q4 sales were ahead of the consensus, though operating profits were somewhat behind the street’s expectations. Also, a better-than-expected 2025 ...
05/02/25
The Q4 earnings were ahead of consensus estimates, driven by a robust showing across key focus areas. Moreover, the 2025 outlook was better than the ...